文献速递慢性静脉疾病

抗血栓治疗与腔内激光消融术后并发症风险的关联

Association between antithrombotic therapy and risk of postoperative complications among patients undergoing endovenous laser ablation.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2017-03-06

这项回顾性队列研究纳入1136例接受980nm二极管激光腔内激光消融的大隐静脉曲张患者,比较抗血栓治疗组与对照组的临床结局和术后并发症。约20%患者接受抗血栓治疗,其中12.4%用抗血小板药、8.4%用抗凝药。全段成功闭塞率达99.9%,抗血栓治疗组与对照组的再通及术后并发症发生率无显著差异,提示腔内激光消融在抗血栓治疗患者中可安全实施。

要点

  • 腔内激光消融全段成功闭塞率达99.9%,围术期无严重并发症。
  • 抗血栓治疗组与对照组的再通和术后并发症发生率无显著差异。
  • 接受抗血栓治疗的患者可安全进行腔内激光消融。

核心结论

  • 抗血栓治疗组腔内激光消融的临床结局和术后并发症与对照组相当,提示该手术在抗血栓治疗患者中可安全实施。

研究设计与样本

  • 回顾性队列研究,纳入2012年1月至2015年11月在本机构接受980nm二极管激光腔内激光消融的1136例日本患者,分为抗血栓治疗组与对照组。

主要发现

  • 约20%患者接受抗血栓治疗,其中141例(12.4%)用抗血小板药、95例(8.4%)用抗凝药。
  • 全段成功闭塞率达99.9%,围术期无严重并发症。
  • 腔内热诱导血栓发生率为2.4%,术后并发症发生率为1.2%。
  • 再通发生1例(0.08%)。
  • 单变量分析显示两组再通和术后并发症发生率无显著差异。

临床怎么用

  • 对接受抗血栓治疗的大隐静脉曲张患者,腔内激光消融可作为安全的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the study was to evaluate the clinical results and postoperative complications, especially recanalization or bleeding complications, in patients with saphenous varicose veins undergoing endovenous laser ablation (EVLA) while receiving antithrombotic therapy (ATT). METHODS: This retrospective cohort study included 1136 Japanese patients undergoing EVLA with a 980-nm diode laser between January 2012 and November 2015 at our institution. The patients were divided into two groups: ATT users (ATT group) and nonusers (control group). The ATT group was further divided into two subgroups according to whether the patients received antiplatelet or anticoagulant therapy. Clinical outcomes and postoperative complications among these patients were assessed. RESULTS: Approximately 20% of the patients undergoing surgery for saphenous varicose veins at our institution received ATT. Of these, 141 (12.4%) received antiplatelet therapy and 95 (8.4%) received anticoagulant therapy. Successful occlusion of the full length of the treated vein was achieved in 99.9% of the patients; there were no severe perioperative complications. Endovenous heat-induced thrombosis occurred in 2.4% of patients, whereas postoperative complications developed in 1.2% of patients. One patient experienced recanalization (0.08%). There were no significant between-group differences in the incidence of recanalization and postoperative complications on univariate analysis. CONCLUSIONS: The clinical outcomes and postoperative complications of EVLA in the ATT group were equivalent to those in the control group, indicating that EVLA can be safely performed in patients receiving ATT.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Takahashi K, Ito H, Katsube T, et al. Association between antithrombotic therapy and risk of postoperative complications among patients undergoing endovenous laser ablation. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 28411700. doi:10.1016/j.jvsv.2016.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。